Related Experiment Video
Updated: May 30, 2026
Enhancing Tumor Content through Tumor Macrodissection
Published on: February 12, 2022
New strategies in diffuse large B-cell lymphoma: translating findings from gene expression analyses into clinical
1University of Rochester Medical Center, Rochester, New York 14642, USA. jonathan_friedberg@urmc.rochester.edu
Abstract:
Gene expression profiling has had a major impact on our understanding of the biology and heterogeneity of diffuse large B-cell lymphoma (DLBCL). Using this technology, investigators can identify biologic subgroups of DLBCL that provide unique targets for rational therapeutic intervention. This review summarizes these potential targets and updates the progress of clinical development of exciting novel agents for the treatment of DLBCL. Results of ongoing studies suggest that in the near future, we will be able to use gene expression profiling, or an accurate surrogate, to define the best therapeutic approach for individual patients with DLBCL.
Insights
Gene expression profiling helps understand diffuse large B-cell lymphoma (DLBCL) biology. This approach identifies targets for new treatments, potentially personalizing DLBCL therapy soon.
Area of Science:
- Oncology
- Genetics
- Immunology
Background:
- Diffuse large B-cell lymphoma (DLBCL) is a heterogeneous disease.
- Gene expression profiling (GEP) has significantly advanced DLBCL research.
- Understanding DLBCL heterogeneity is crucial for targeted therapy.
Purpose of the Study:
- To review potential therapeutic targets identified through GEP in DLBCL.
- To update on the clinical development of novel agents for DLBCL treatment.
- To highlight the future role of GEP in personalizing DLBCL therapy.
Main Methods:
- Review of scientific literature on GEP in DLBCL.
- Analysis of ongoing clinical trials for novel DLBCL agents.
- Synthesis of data on biologic subgroups and therapeutic targets.
Main Results:
- GEP identifies distinct biologic subgroups within DLBCL.
- These subgroups represent unique targets for novel therapeutic interventions.
- Several novel agents are in clinical development for DLBCL treatment.
Conclusions:
- GEP is a powerful tool for dissecting DLBCL heterogeneity.
- Targeted therapies based on GEP are emerging for DLBCL.
- Future treatment strategies for DLBCL may involve GEP-based patient stratification.
